Empagliflozin/metformin

Drug Profile

Empagliflozin/metformin

Alternative Names: BI-10773/metformin; Empagliflozin/metformin extended-release; Empagliflozin/metformin immediate-release; Metformin/BI-10773; Metformin/empagliflozin; Metformin/empagliflozin extended-release; Metformin/empagliflozin immediate-release; Metformin/empagliflozin XR; Synjardy; Synjardy XR

Latest Information Update: 06 May 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cyclic ethers; Glucosides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 25 Apr 2017 Empagliflozin/metformin extended release (Synjardy® XR) launched in the US for Type-2 diabetes mellitus
  • 25 Apr 2017 European Commission approves change in the label to the indication statement and inclusion of data on reduction of risk of cardiovascular death in patients with established cardiovascular disease
  • 26 Jan 2017 The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for change in the terms of the marketing authorisation of empagliflozin/metformin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top